FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SPOON ALAN G
2. Issuer Name and Ticker or Trading Symbol

DANAHER CORP /DE/ [ DHR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

2200 PENNSYLVANIA AVENUE, NW, SUITE 800W
3. Date of Earliest Transaction (MM/DD/YYYY)

10/25/2019
(Street)

WASHINGTON, DC 20037
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom shares (1) $0 (2) 10/25/2019    A     249.111       (3)  (3) Common stock (1) 249.111 (1) $135.87 (1) 22877.402  D 
 

Explanation of Responses:
(1)  Under the terms of the Non-Employee Directors Deferred Compensation Plan (the "Plan") established under the Danaher Corporation 2007 Omnibus Incentive Plan, the reporting person can defer all or part of the cash director fees he is entitled to receive each quarter. Amounts deferred under the plan are converted into a particular number of notional shares of Danaher common stock, calculated based on the closing price of Danaher's common stock on the quarterly date such fees otherwise would have been paid. The price shown in Table II, Column 8 above is the closing price per share of the Danaher common stock as reported on the NYSE on the transaction date noted above. The phantom shares reported reflect contributions to the reporting person's account under the Plan as well as dividend equivalents accrued to the reporting person's account.
(2)  Upon distribution, the phantom shares convert into shares of Danaher common stock on a one-for-one basis.
(3)  The reporting person is fully vested in all amounts deferred under the Plan.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SPOON ALAN G
2200 PENNSYLVANIA AVENUE, NW
SUITE 800W
WASHINGTON, DC 20037
X



Signatures
James F. O'Reilly, attorney-in-fact for Alan G. Spoon 10/28/2019
**Signature of Reporting Person Date


Danaher (NYSE:DHR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Danaher Charts.
Danaher (NYSE:DHR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Danaher Charts.

Danaher Corp /de/ News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
Friday 3 May 2024 (16 hours ago) • PR Newswire (US)
Danaher Reports First Quarter 2024 Results
Tuesday 23 April 2024 (2 weeks ago) • PR Newswire (US)
Danaher Schedules First Quarter 2024 Earnings Conference Call
Friday 22 March 2024 (1 month ago) • PR Newswire (US)
Danaher to Present at TD Cowen Health Care Conference
Wednesday 28 February 2024 (2 months ago) • PR Newswire (US)
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
Friday 23 February 2024 (2 months ago) • PR Newswire (US)
Danaher Announces Quarterly Dividend
Thursday 22 February 2024 (2 months ago) • PR Newswire (US)
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
Monday 5 February 2024 (3 months ago) • PR Newswire (US)
Danaher Reports Fourth Quarter and Full Year 2023 Results
Tuesday 30 January 2024 (3 months ago) • PR Newswire (US)
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
Tuesday 9 January 2024 (4 months ago) • PR Newswire (US)
Danaher Says 4Q Adjusted. Revenue to Fall by Less Than Forecast
Tuesday 9 January 2024 (4 months ago) • Dow Jones News
Danaher CEO to Comment on Financial Performance
Tuesday 9 January 2024 (4 months ago) • PR Newswire (US)
Danaher to Present at J.P. Morgan Healthcare Conference
Wednesday 3 January 2024 (4 months ago) • PR Newswire (US)